|
question about this Trial Trastuzumab-MCC-DM1
Hey My sister's I went ot my visit Doc today and he just order a blood test to check if I' still have estrogen on my ovaries depend the results he will put me on xeloda , aromate inhibitors o femara ? and I also ask about clinical trial and he mencioned trial trastuzumad -MCC_DM1 witch is the same that BARBARA H. is using ..so far with good results ...I dont know if I qualified yet ...so any thoughs are very very welcome .... |
http://www.clinicaltrials.gov/ct/sea...&submit=Search
Here is a link to the trial. This sounds very exciting to me! <CENTER>A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer This study is currently recruiting participants.<SMALL> Verified by Genentech September 2007</SMALL> <TABLE cellSpacing=0 cellPadding=0 align=center bgColor=#cccccc border=0><TBODY><TR><TD><TABLE cellSpacing=1 cellPadding=3 width="100%" border=0><TBODY><TR><TH style="VERTICAL-ALIGN: top; TEXT-ALIGN: right" bgColor=#ffffff>Sponsored by:</TH><TD bgColor=#ffffff>Genentech</TD></TR><TR><TH style="VERTICAL-ALIGN: top; TEXT-ALIGN: right" bgColor=#ffffff>Information provided by:</TH><TD bgColor=#ffffff>Genentech</TD></TR><TR><TH style="VERTICAL-ALIGN: top; TEXT-ALIGN: right" bgColor=#ffffff>ClinicalTrials.gov Identifier:</TH><TD bgColor=#ffffff>NCT00509769</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE> </CENTER>http://www.clinicaltrials.gov/html/images/arrow2.gif Purpose This is a multi-institutional, open-label, single-arm, Phase II study of T-DM1 administered by IV infusion to patients with HER2-positive MBC. A total of at least 100 efficacy-evaluable patients are planned to be enrolled. <TABLE cellSpacing=0 cellPadding=2 width="95%" summary="Summary of information about the study.Includes condition under study, intervention, and study phase if available." border=1><TBODY><TR><TH class=tablehead vAlign=top align=left>Condition </TH><TH class=tablehead vAlign=top align=left>Intervention</TH><TH class=tablehead vAlign=top align=left>Phase</TH></TR><TR><TD vAlign=top align=left>Metastatic Breast Cancer </TD><TD vAlign=top align=left> Drug: Trastuzumab-MCC-DM1 </TD><TD vAlign=top align=left>Phase II </TD></TR></TBODY></TABLE> MedlinePlus related topics: Breast Cancer; Cancer Genetics Home Reference related topics: Cancer; breast cancer Study Type: Interventional Study Design: Treatment Official Title: A Phase II, Single-Arm, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy Further study details as provided by Genentech: Primary Outcome Measures:
Study start: July 2007 http://www.clinicaltrials.gov/html/images/arrow2.gif Eligibility Genders Eligible for Study: Both Criteria Inclusion Criteria:
Please refer to this study by ClinicalTrials.gov identifier NCT00509769 United States, Arkansas Little Rock Hem Onc Assoc, Little Rock, Arkansas, 72205, United States; Recruiting Carol Winters 501-907-6177 Ext. 427 cwinters@lrho.org United States, Colorado Rocky Mountain Cancer Center, Longmont, Colorado, 80501, United States; Recruiting Joni Richman 303-285-5011 joni.richman@usoncology.com United States, District of Columbia Washington Cancer Institute, Washington, District of Columbia, 20010, United States; Recruiting Lauren Callahan 202-877-8448 lauren.j.callahan@medstar.net United States, Florida Florida Cancer Care, Davie, Florida, 33328, United States; Recruiting Joel Espinoza 954-262-7606 crc@flcancercare.com Gulfcoast Oncology Associates, Saint Petersburg, Florida, 33705, United States; Recruiting Margie Blasek 727-821-0017 smyers@gulfcoastoncology.com Hem/Onc Assoc - Treasure Coast, Port St Lucie, Florida, 34952, United States; Recruiting Christine Baker-Gerdes 772-408-5159 cgerdes@hemoncfl.com Bay Area Oncology, Tampa, Florida, 33607, United States; Recruiting Julie Hahn 813-875-2300 Ext. 28 jhahn@bayareaoncology.com United States, Illinois John McClean, M.D. - Private P, Galesburg, Illinois, 61401, United States; Recruiting Linda Ferry 309-343-3024 lferry@grics.net United States, Iowa Cedar Valley Med Specialists, Waterloo, Iowa, 50702, United States; Recruiting Kim Maxfield 319-272-2700 kmaxfield@cvmspc.com United States, Kentucky Kentuckiana Cancer Institute, Louisville, Kentucky, 40202, United States; Recruiting Leslie Haysley 502-561-8200 lhaysley@kci.us United States, Minnesota Minnesota Oncology Hematology,, Minneapolis, Minnesota, 55404, United States; Recruiting Lynn Anderson 952-928-2992 lynn.anderson@usoncology.com United States, Missouri Kansas City Cancer Center, LLC, Lee's Summit, Missouri, 64064, United States; Recruiting Vickie Thomas 913-541-4641 vickie.thomas@usoncology.com St. Louis Cancer and Breast Inst, Saint Louis, Missouri, 63141, United States; Recruiting Kelly Tschannen 314-983-4936 ktschannen@stlcancer.com USO, Columbia, Missouri, 65201, United States; Recruiting Lisa Mision 573-817-8538 lisa.mision@USOncology.com United States, New York New York Oncology Hematology, Albany, New York, 12206, United States; Recruiting Michele Butler 518-489-2607 michele.butler@usoncology.com United States, North Carolina Raleigh Hemotology and Oncology, Raleigh, North Carolina, 27607, United States; Recruiting Diane Bracco 919-785-4909 diane.bracco@usoncology.com Carolinas Hem-Oncology Assoc, Charlotte, North Carolina, 28203, United States; Recruiting Margot Church 704-355-8298 margot.church@carolinashealthcare.org United States, Oregon Midwestern Regional Med Center, Eugene, Oregon, 97401-8122, United States; Recruiting Cynthia Cabrera 541-681-4930 cynthia.cabrera@usoncology.com United States, Texas Sammons Cancer Center, Dallas, Texas, 75246, United States; Recruiting Marnie Fisher 214-370-1038 marnie.fisher@usoncology.com Texas Oncology Cancer Center, Austin, Texas, 78731, United States; Recruiting Gabriella Iannone 512-427-9467 gabriella.iannone@usoncology.com Texas Oncology PA, Fort Worth, Texas, 76104, United States; Recruiting Nori Sullivan 817-850-2000 nori.sullivan@USOncology.com Texas Oncology, P.A., Dallas, Texas, 75231-4400, United States; Recruiting Myrna Williamson 214-739-4175 myrna.williamson@usoncology.com Texas Oncology, P.A., Bedford, Texas, 76022, United States; Recruiting Cynthia Schoenfeldt 817-359-9033 cynthia.schoenfeldt@usoncology.com Texas Oncology, P.A., Houston, Texas, 77024-2305, United States; Recruiting Dorothy Caldwell 713-467-1722 dorothy.caldwell@usoncology.com US Oncology, Midland, Texas, 79701, United States; Recruiting Mary Williams 432-688-0821 Mary.Williams2@USOncology.com USO, Dallas, Texas, 75230-2510, United States; Recruiting Rhonda Waldrop 972-566-7790 rhonda.waldrop@usoncology.com USO - Tyler Cancer Ctr, Tyler, Texas, 75702, United States; Recruiting Linda Dunklin 903-579-9800 linda.dunklin@USOncology.com Waco Cancer Care and Research Ce, Waco, Texas, 76712, United States; Recruiting Theresa Schroeder 254-399-0741 theresa.schroeder@usoncology.com Cancer Specialists of South Te, Corpus Christi, Texas, 78412, United States; Recruiting Katrina Powell 361-993-3456 kpowell@corpuschristicancer.com United States, Virginia Fairfax N Virginia Hem/Onc PC, Fairfax, Virginia, 22031, United States; Recruiting Denise Campbell 703-208-9260 denise.campbell@USOncology.com United States, Washington Northwest Cancer Specialists, Vancouver, Washington, 98684, United States; Recruiting Michelle Jones 360-573-0471 michelle.jones@USOncology.com Northwest Medical Specialties, Tacoma, Washington, 98405, United States; Recruiting Linda Dhaene 253-428-8753 LDhaene@nwmsonline.com Study chairs or principal investigators Scott Holden, M.D., Study Director, Genentech http://www.clinicaltrials.gov/html/images/arrow2.gif More Information Study ID Numbers: TDM4258g Last Updated: September 24, 2007 Record first received: July 27, 2007 ClinicalTrials.gov Identifier: NCT00509769 Health Authority: United States: Food and Drug Administration ClinicalTrials.gov processed this record on October 01, 2007 |
| All times are GMT -7. The time now is 01:35 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021